Phio Pharmaceuticals Corp. (PHIO): auditor change — Phio Pharmaceuticals dismisses BDO and engages Grant Thornton as auditor

Phio Pharmaceuticals Corp.

Audit Committee dismissed BDO USA as independent auditor effective April 17, 2025.
Grant Thornton LLP appointed as new independent auditor for fiscal year ending Dec 31, 2025.
No disagreements or reportable events occurred during BDO's tenure through April 17, 2025.
BDO's reports for FY2024 and FY2023 included going-concern explanatory paragraphs.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.99

Phio Pharmaceuticals Corp. engaged Grant Thornton LLP as its auditor.

Action: engagement
Auditor: Grant Thornton LLP

Exact text from the filing

Also on April 17, 2025, the Audit Committee approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.99

Phio Pharmaceuticals Corp. dismissed BDO USA, P.C. as its auditor.

Action: dismissal
Auditor: BDO USA, P.C.
Successor: Grant Thornton LLP

Exact text from the filing

on April 17, 2025, the Audit Committee approved the dismissal of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm, effective immediately.

View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-25-002725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.